^
Association details:
| Biomarker: | CDKN2A promoter methylation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer
Published date:
01/01/2021
Excerpt:
In these 49 GC cell lines, Epstein–Barr virus (EBV) and high microsatellite instability (MSI-H)-type cell lines were p16 methylated and sensitive to abemaciclib; further, genomically stable (GS), and chromosomal instability (CIN)-type cell lines with p16 methylation and intact Rb were also found to be responsive.
DOI:
10.1016/j.bcp.2020.114320
